Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. - Wikidata - awgldk - TriplyDB

Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.

Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.

http://www.wikidata.org/entity/Q37857335

about

Ivabradine, coronary artery disease, and heart failure: beyond rhythm control Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using magnetic resonance imaging technique.Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.Ivabradine: A Review of Labeled and Off-Label Uses.Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.Role of ivabradine in management of stable angina in patients with different clinical profiles.

P2860

Q26865770-CD60DF47-2083-48D3-893D-A0B1C92126D2 Q35008305-67920E35-C2BB-46C5-AB84-D709E5AEF65F Q36943413-D4DF7A0E-74FC-4D30-8FC2-F32FA109C075 Q38142792-8BCAE14A-1D2E-45F4-A24C-E1C06389624E Q38894220-2F36BFFC-BA91-4668-89A0-E046DB7D3960 Q51662386-EC2CE483-37D6-4F0E-AA6D-D8EF4D586497 Q54961020-4651FB1A-0305-4A71-B0AB-22DB279F20EF

P2860

Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.

http://www.wikidata.org/entity/Q37857335

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Innovation in coronary artery ...... ate reduction with ivabradine.

@en

Innovation in coronary artery ...... ate reduction with ivabradine.

@nl

type

label

Innovation in coronary artery ...... ate reduction with ivabradine.

@en

Innovation in coronary artery ...... ate reduction with ivabradine.

@nl

prefLabel

Innovation in coronary artery ...... ate reduction with ivabradine.

@en

Innovation in coronary artery ...... ate reduction with ivabradine.

@nl

P1433

Q37857335-447F2C5B-6CFF-4A32-AAC1-09A364037265

P1476

Q37857335-3FE47739-8FCF-4AA3-8E3A-ABAB340E940A

P2093

Q37857335-22323F69-B71F-430A-A331-7494B6A3CDAA

Q37857335-489F479F-4E09-4564-9A7A-B4F51A734317

Q37857335-84891181-0023-41C2-8EE3-EA036CF1474B

P2860

Q37857335-057054B3-4054-4C11-B9E7-FF65B72930CC

Q37857335-15850D94-09D5-43DB-B7FE-E073D45D1E04

Q37857335-1B0D394A-DE9B-4077-BA32-8DC2365FCF04

Q37857335-1FAEFB3B-7A45-4150-841B-FFF351CF8DCD

Q37857335-2423767A-9911-46AE-8CCC-1E79A36F6CB1

Q37857335-28EC161D-3EEB-4883-88B2-A110F38ACF1D

Q37857335-297EB0CD-3D8C-4814-B83E-4A99C7973FA3

Q37857335-4542EE58-9EAB-40A6-A80F-27FDB3780D98

Q37857335-47A13B3C-86DD-491E-9A07-D039DD87AA29

Q37857335-50044BBA-D9BA-428C-BE29-B925573DFCBF

P304

Q37857335-4E82E92E-69F4-4439-9F82-04CAC05387F1

P31

Q37857335-33B4C884-0D50-4BBA-A96F-FA2B65EADC4D

P356

Q37857335-5022B672-AA97-4AAF-9277-54FC4D2835CB

P407

Q37857335-F8C06AD3-5F37-47FB-8CFB-19E442AC1A8F

P478

Q37857335-183A0A65-0AF0-424E-B76E-F8D1B586CF38

P577

Q37857335-2F87B908-F0CE-4069-99EF-BFBDB5BB96F5

P698

Q37857335-09129FA2-F5E2-446C-8D5C-F4B8173F3870

P921

Q37857335-DCD6F12D-6903-4FF7-966D-EB73A863B07F

P356

J.1749-6632.2011.05960.X

P1433

Annals of the New York Academy of Sciences

P1476

Innovation in coronary artery ...... ate reduction with ivabradine.

@en

P2093

Emmanuel Canet

http://www.w3.org/2001/XMLSchema#string

Guy Lerebours

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Vilaine

http://www.w3.org/2001/XMLSchema#string

P2860

Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).

Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Influence of heart rate on mortality after acute myocardial infarction.

P304

90-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1749-6632.2011.05960.X

http://www.w3.org/2001/XMLSchema#string

P407

P478

1222

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21434947

http://www.w3.org/2001/XMLSchema#string

P921